Literature DB >> 29265134

Ultrafast charge-conversional nanocarrier for tumor-acidity-activated targeted drug elivery.

Jing Liu1, Shoaib Iqbal, Xiao-Jiao Du, Youyong Yuan, Xianzhu Yang, Hong-Jun Li, Jun Wang.   

Abstract

Nanocarriers with tumor-acidity-activated charge-conversional ability are of particular interest for targeted drug delivery in the field of precision nanomedicine. Nevertheless, the key challenge of this strategy is the slowness of reversing the surface charge at the tumor tissue. As a proof-of-concept, we synthesized the amphiphilic triblock polymer poly(ethylene glycol)-block-poly(2-carboxyethylacrylate)-block-poly(2-azepaneethylmethacrylate) (PEG-b-PCEA-b-PAEMA) to prepare the cisplatin-loaded nanocarrier UCC-NP/Pt. The PAEMA block at the physiological pH values was hydrophobic, which formed the core of UCC-NP/Pt. In contrast, at the tumor acidity, the tertiary amine groups of PAEMA block rapidly protonated, resulting in the ultrafast charge conversion of UCC-NP/Pt within 10 s. Such ultrafast charge-conversional effect more efficiently enhanced tumor cell internalization of nanocarriers, thus achieving targeted drug delivery, which in turn exhibited superior anticancer efficacy even in the cisplatin-resistant cells. This approach provides new avenues for tumor-acidity-activated targeted drug delivery.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29265134     DOI: 10.1039/c7bm01025g

Source DB:  PubMed          Journal:  Biomater Sci        ISSN: 2047-4830            Impact factor:   6.843


  2 in total

1.  Intelligent nanogels with self-adaptive responsiveness for improved tumor drug delivery and augmented chemotherapy.

Authors:  Xin Li; Helin Li; Changchang Zhang; Andrij Pich; Lingxi Xing; Xiangyang Shi
Journal:  Bioact Mater       Date:  2021-03-24

2.  Light-controllable charge-reversal nanoparticles with polyinosinic-polycytidylic acid for enhancing immunotherapy of triple negative breast cancer.

Authors:  Lei Fang; Zitong Zhao; Jue Wang; Ping Xiao; Xiangshi Sun; Yaping Ding; Pengcheng Zhang; Dangge Wang; Yaping Li
Journal:  Acta Pharm Sin B       Date:  2021-06-15       Impact factor: 11.413

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.